Literature DB >> 15547185

Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.

Wenrui Duan1, Li Gao, Lawrence J Druhan, Wei-Guo Zhu, Carl Morrison, Gregory A Otterson, Miguel A Villalona-Calero.   

Abstract

Maintenance of p53 function is important for normal cell growth and development, and loss of p53 function contributes directly to malignant tumor development. The recently discovered Pirh2 protein is an ubiquitin-protein ligase that negatively regulates p53 through activity by targeting it for degradation. To determine how Pirh2 may mediate lung tumorigenesis, we evaluated Pirh2 expression in human and mouse lung tumor samples and paired normal lung tissues using immunoblot analysis and immunohistochemistry. Pirh2 protein expression was higher in 27 (84%) of 32 human lung neoplasms than in matched normal lung tissue and in 14 of 15 mouse lung tumors evaluated. In addition, p53 protein was more ubiquitinated in the mouse lung tumors than in normal tissue, and overall p53 expression was lower than that in normal tissue. These results are consistent with the hypothesis that increased Pirh2 expression affects lung tumorigenesis by reducing p53 activity. To our knowledge, this is the first description of altered Pirh2 expression in human and mouse tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547185     DOI: 10.1093/jnci/djh292

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  43 in total

1.  Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.

Authors:  Lan Wang; Guifen He; Pingzhao Zhang; Xiang Wang; Mei Jiang; Long Yu
Journal:  Mol Biol Rep       Date:  2010-03-24       Impact factor: 2.316

2.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

3.  Dynamic changes of PIRH2 and p27kip1 expression in injured rat sciatic nerve.

Authors:  Honghui Li; Jie Deng; Haili Chen; Tao Chen; Xiang Cao; Huibao Hou; Weipeng Huan; Guowei Zhang; Biyun Yu; Youhua Wang
Journal:  Neurol Sci       Date:  2011-09-30       Impact factor: 3.307

Review 4.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

5.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

6.  It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Authors:  Ian M Love; Steven R Grossman
Journal:  Genes Cancer       Date:  2012-03

7.  PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.

Authors:  Gang Zheng; Jinying Ning; Yu-Chung Yang
Journal:  Biochem Biophys Res Commun       Date:  2007-10-11       Impact factor: 3.575

8.  Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.

Authors:  Yuan Su; Liping Zhu; Yang Jin; Xiaoju Zhang; Qiong Zhou; Ming Bai
Journal:  Front Med China       Date:  2007-10-01

9.  Molecular basis of Pirh2-mediated p53 ubiquitylation.

Authors:  Yi Sheng; Rob C Laister; Alexander Lemak; Bin Wu; Elizabeth Tai; Shili Duan; Jonathan Lukin; Maria Sunnerhagen; Sampath Srisailam; Murthy Karra; Sam Benchimol; Cheryl H Arrowsmith
Journal:  Nat Struct Mol Biol       Date:  2008-11-30       Impact factor: 15.369

10.  Bi-directional SIFT predicts a subset of activating mutations.

Authors:  William Lee; Yan Zhang; Kiran Mukhyala; Robert A Lazarus; Zemin Zhang
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.